SS-31 (Elamipretide): What It Is, How It Works, Research & Safety

SS-31 is the research name for elamipretide, a synthetic mitochondria-targeted tetrapeptide that has been studied for its ability to interact with cardiolipin in the inner mitochondrial membrane.

Mitochondria are often described as the energy-producing structures of cells, but their functions extend well beyond energy production. They participate in cellular signaling, metabolism, oxidative processes and programmed cell death. Because mitochondrial dysfunction is associated with numerous diseases, researchers have investigated therapies designed to act directly on mitochondrial structures.

Elamipretide is one of the most extensively studied compounds in this area. Research has examined its effects on mitochondrial membrane structure, cardiolipin, cellular bioenergetics and oxidative stress.

Importantly, SS-31 should not be presented as a general-purpose wellness or anti-aging peptide. Its clinical status is more specific: in September 2025, the U.S. Food and Drug Administration granted accelerated approval to Forzinity (elamipretide) injection for improving muscle strength in patients with Barth syndrome weighing at least 30 kg.

What Is SS-31?

SS-31 is a synthetic tetrapeptide belonging to the Szeto-Schiller peptide family. Its development has focused on targeting mitochondria rather than acting primarily on receptors at the cell surface.

The compound is also known by several names, including:

• SS-31
• SS31
• Elamipretide
• MTP-131
• Bendavia

A central feature of elamipretide is its interaction with cardiolipin, a distinctive phospholipid found in the inner mitochondrial membrane. Research suggests that this interaction can influence mitochondrial membrane properties and proteins involved in mitochondrial energy metabolism.

How Does SS-31 Work?

The proposed mechanism of SS-31 is closely associated with cardiolipin.

Cardiolipin helps organize the inner mitochondrial membrane and supports the structure and function of proteins involved in oxidative phosphorylation. SS-31 selectively interacts with cardiolipin through electrostatic and hydrophobic interactions.

Research has suggested that this interaction can affect membrane organization, mitochondrial protein complexes and electron transport. Studies have also examined SS-31’s effects on the interaction between cardiolipin and cytochrome c, a protein involved in mitochondrial electron transport and cellular signaling.

More recent mechanistic research has expanded beyond the original description of SS-31 as simply a mitochondrial antioxidant. Investigators have reported effects involving mitochondrial membrane electrostatics, cardiolipin-dependent protein organization and mitochondrial bioenergetics.

This distinction is important for accurate SEO content: SS-31 is better described as a mitochondria-targeted peptide that interacts with cardiolipin than simply as an “antioxidant peptide.”

SS-31 and Mitochondrial Function

Mitochondrial function depends on the integrity of the inner mitochondrial membrane.

The membrane contains components of the electron transport system that help generate the electrochemical gradient used to produce ATP, the primary energy currency of cells. Cardiolipin contributes to the organization and function of this membrane environment.

Laboratory studies have reported that SS-31 can influence mitochondrial respiration and ATP synthesis under specific experimental conditions. Research has also investigated its ability to protect mitochondrial structures from processes associated with oxidative damage.

However, laboratory findings should not automatically be interpreted as evidence that SS-31 improves mitochondrial function in healthy people.

The distinction between biological mechanism, preclinical evidence and demonstrated clinical benefit is particularly important when discussing experimental peptides.

SS-31 and Cardiolipin

Cardiolipin is one of the defining features of the mitochondrial inner membrane.

Unlike many other cellular phospholipids, cardiolipin has a distinctive structure that allows it to participate in membrane organization and interactions with mitochondrial proteins. It is involved in maintaining mitochondrial architecture and supporting respiratory processes.

SS-31’s affinity for cardiolipin is therefore central to its proposed mechanism.

Studies have found that SS-31 binds to cardiolipin-containing membranes and can modify membrane surface electrostatics. Researchers have proposed that these changes may influence ion distribution, lipid organization and interactions between cardiolipin and mitochondrial proteins.

This provides a scientific basis for investigating elamipretide in diseases where mitochondrial dysfunction or cardiolipin abnormalities are involved.

SS-31 and Barth Syndrome

One of the most significant developments in the clinical history of SS-31 is its application to Barth syndrome, a rare genetic mitochondrial disorder associated with abnormalities in cardiolipin remodeling.

Barth syndrome can involve cardiomyopathy, skeletal muscle weakness, neutropenia and growth abnormalities. The underlying disorder affects the TAFAZZIN gene and consequently interferes with normal cardiolipin remodeling.

In September 2025, the FDA granted accelerated approval to Forzinity (elamipretide) for improving muscle strength in patients with Barth syndrome who weigh at least 30 kg. The FDA described the approval as the first treatment for Barth syndrome.

This approval is an important milestone because it moves elamipretide beyond purely experimental research for this particular indication.

It is nevertheless important to distinguish FDA-approved elamipretide for its authorized indication from unapproved or research-use SS-31 products marketed online for unrelated purposes.

SS-31 Clinical Research

Before its approval for Barth syndrome, elamipretide had been investigated across a range of mitochondrial and cardiovascular conditions.

Clinical and preclinical research has explored areas including:

• Primary mitochondrial myopathy
• Barth syndrome
• Cardiovascular disease
• Heart failure
• Age-related mitochondrial dysfunction
• Ophthalmic conditions
• Skeletal muscle dysfunction
• Other disorders involving mitochondrial impairment

A 2025 review summarized research involving trials such as PROGRESS-HF, TAZPOWER, MMPOWER-3 and ReCLAIM, while emphasizing that results have varied according to disease and clinical endpoint.

A separate 2025 review described completed and ongoing research involving Barth syndrome, primary mitochondrial myopathy and age-related macular degeneration, highlighting both the mechanistic rationale and the remaining translational questions.

SS-31 and Cardiovascular Research

Mitochondria play a major role in the energy demands of cardiac muscle, making mitochondrial dysfunction an important area of cardiovascular research.

Preclinical studies of elamipretide have investigated mitochondrial respiration, cardiac energy metabolism and heart function. Research has also examined whether targeting cardiolipin can influence mitochondrial abnormalities associated with heart failure.

These findings provide a scientific rationale for further investigation but should not be interpreted as proof that SS-31 is an established treatment for heart failure.

Clinical outcomes must be evaluated separately for each disease, population and treatment endpoint.

SS-31 and Mitochondrial Myopathy Research

Primary mitochondrial myopathies are a group of disorders in which mitochondrial abnormalities can affect skeletal muscle and other organs.

Because skeletal muscle has high energy requirements, impaired mitochondrial bioenergetics can contribute to weakness and exercise intolerance.

Elamipretide has therefore been investigated as a potential mitochondrial-targeted therapy. Clinical studies have evaluated outcomes such as exercise capacity, muscle performance and mitochondrial biomarkers.

The results have not established SS-31 as a universal treatment for mitochondrial disease. Instead, research continues to determine which patient populations and disease mechanisms may benefit most from mitochondrial-targeted therapies.

Potential Applications of SS-31

Research into SS-31 has extended beyond Barth syndrome.

Scientists have investigated possible applications in conditions involving mitochondrial dysfunction, including cardiovascular, muscular, neurological, renal and ophthalmic disorders.

Preclinical research can be valuable for identifying biological mechanisms and potential therapeutic pathways. However, evidence from cell cultures and animal models cannot by itself establish effectiveness in humans.

Recent reviews continue to describe elamipretide as a promising mitochondrial therapeutic while also noting challenges involving clinical translation, long-term safety, bioavailability and variability between disease models.

Therefore, terms such as “potential application,” “under investigation” and “research compound” are more appropriate for non-approved uses than definitive claims of treatment effectiveness.

Is SS-31 FDA Approved?

The answer requires an important distinction.

Elamipretide is FDA-approved for a specific indication: Forzinity (elamipretide) injection received accelerated approval in September 2025 for improving muscle strength in patients with Barth syndrome weighing at least 30 kg.

That does not mean that all products labeled “SS-31” are FDA-approved.

Nor does the approval establish elamipretide as an approved treatment for:

• General mitochondrial health
• Anti-aging
• Athletic performance
• Fat loss
• General energy enhancement
• Cognitive enhancement
• Healthy people’s mitochondrial optimization

SEO content should make this distinction clearly to avoid misleading readers.

SS-31 Safety and Side Effects

The safety profile of elamipretide depends on the formulation, indication, patient population and clinical setting.

Because the compound has progressed into regulated clinical use for Barth syndrome, safety information is more substantial than it was during its early research stages. Nevertheless, this should not be generalized to every unregulated product marketed as “SS-31.”

People should distinguish between prescription elamipretide manufactured under pharmaceutical quality standards and products sold online as research peptides.

Anyone considering elamipretide for a medical condition should discuss the treatment with an appropriately qualified healthcare professional.

SS-31 vs. Other Peptides

SS-31 differs from many peptides commonly marketed online.

Rather than primarily acting as a hormone analogue or growth-related signaling molecule, elamipretide was designed to target mitochondria and interact with cardiolipin.

This gives SS-31 a distinctive research profile focused on mitochondrial membrane biology and bioenergetics.

However, “mitochondria-targeted peptide” does not automatically mean “better” than other therapeutic approaches. The appropriate treatment depends on the disease, clinical evidence, regulatory status and individual patient circumstances.

Why Research-Grade SS-31 Requires Caution

Online peptide markets sometimes use terms such as “research grade,” “laboratory peptide” or “99% purity.”

Such terminology does not necessarily mean that a product has been evaluated as a medicine.

Potential concerns with unregulated peptide products can include:

• Uncertain identity
• Variable concentration
• Impurities
• Contamination
• Inadequate sterility
• Incorrect storage
• Inconsistent manufacturing
• Lack of validated clinical dosing information

Consequently, published studies of pharmaceutical-quality elamipretide should not be assumed to validate every product sold under the SS-31 name.

The Future of SS-31 Research

The development of elamipretide illustrates the growing interest in mitochondria as therapeutic targets.

Research is increasingly examining the mitochondrial inner membrane as an active therapeutic target rather than treating mitochondrial dysfunction solely through conventional antioxidant approaches.

Recent mechanistic studies have improved understanding of how SS-31 interacts with cardiolipin and mitochondrial membranes. Future research may help clarify which diseases are most responsive to cardiolipin-targeted therapies and which biomarkers can predict treatment response.

The FDA approval of elamipretide for Barth syndrome also provides an important clinical foundation for continued research into mitochondrial medicine.

Frequently Asked Questions About SS-31

What is SS-31?

SS-31 is the research name for elamipretide, a mitochondria-targeted synthetic tetrapeptide designed to interact with cardiolipin in the inner mitochondrial membrane.

What is SS-31 also called?

SS-31 is also known as elamipretide, MTP-131 and Bendavia.

How does SS-31 work?

Research indicates that SS-31 selectively interacts with cardiolipin and can influence mitochondrial membrane properties, protein organization and bioenergetic processes.

What is cardiolipin?

Cardiolipin is a distinctive phospholipid found in the inner mitochondrial membrane. It contributes to mitochondrial membrane organization and supports the function of proteins involved in energy metabolism.

Is SS-31 FDA approved?

Elamipretide is FDA-approved as Forzinity for improving muscle strength in patients with Barth syndrome who weigh at least 30 kg. It is not generally approved as an anti-aging, athletic-performance or general mitochondrial-health treatment.

Is SS-31 the same as elamipretide?

Yes. SS-31 is the research designation commonly associated with elamipretide.

Is SS-31 an antioxidant?

SS-31 has been investigated for effects associated with oxidative stress and mitochondrial protection. However, describing it simply as an antioxidant does not capture its more specific interaction with cardiolipin and mitochondrial membranes.

What diseases have been studied with SS-31?

Research has examined elamipretide in areas including Barth syndrome, primary mitochondrial myopathy, cardiovascular disease and ophthalmic conditions, among others. Evidence varies considerably by indication.

Is SS-31 approved for anti-aging?

No. FDA approval of elamipretide is specific to its authorized Barth syndrome indication and should not be interpreted as approval for anti-aging or general longevity purposes.

Is SS-31 approved for athletic performance?

No. The FDA approval for elamipretide does not establish it as an approved athletic-performance treatment.

Is SS-31 the same as other mitochondrial peptides?

Not necessarily. SS-31 has a specific molecular structure and mechanism centered on mitochondrial targeting and cardiolipin interaction. Different mitochondrial-targeted compounds can have substantially different mechanisms and clinical evidence.

Conclusion

SS-31, or elamipretide, is a mitochondria-targeted tetrapeptide that has generated significant scientific interest because of its interaction with cardiolipin and the mitochondrial inner membrane.

Research has investigated its effects on mitochondrial membrane organization, oxidative processes, electron transport and cellular bioenergetics. Clinical development has covered several disease areas, with particularly important progress in Barth syndrome.